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Summary Apoptosis plays an important role in cardiovascular diseases such as atherosclero-
sis, ischemic heart disease, and congestive heart failure. Previous studies have demonstrated
that oxidative stress, physiological stress, and inﬂammatory cytokines such as tumor necrosis
factor and Fas ligand are involved in apoptosis of cardiovascular system. We demonstrate that
another apoptosis-related pathway, i.e. granzyme B/perforin system is involved in cardiovascu-
lar diseases. Expression of granzyme B, a member of serine protease family is increased in acute
coronary syndrome, coronary artery disease with end-stage renal disease, and subacute stage
of acute myocardial infarction. Although granzyme B is extensively researched in immunological
disorders, the role of granzyme B/perforin system was not clear in the cardiovascular ﬁeld. In
addition, little is known regarding the inhibition of granzyme B system in the clinical situation.
In this review we demonstrate recent ﬁndings of granzyme B in cardiovascular diseases and
possible therapeutic applications of inhibiting the granzyme B/perforin system.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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ntroduction
therosclerosis has been found to be induced by complex
rocesses including lipid accumulation, cellular migration,
nﬂammation, matrix remodeling, and apoptosis. Apoptosis
s supposed to play important roles in cardiovascular dis-
ases [1]. It has been reported that apoptosis is involved in
rogression of atherosclerosis, plaque rupture, and extracel-
ular matrix remodeling [2—4]. Apoptosis has been found to
e induced by a number of mechanisms, including oxidative
tress, serum deprivation, chemical inducers, ultraviolet
xposure, thermal stress, and cytokines. Several cytokines
re found to induce apoptosis by binding to their speciﬁc
eceptors. Most of these ‘‘death-ligands’’ belong to the
umor necrosis factor (TNF) family, including TNF, lympho-
oxin , Fas ligand, and TRAIL/Apo2L.
There has been a report of the critical role of cytotoxic
mmune responses as a mediator of apoptotic cell death in
therosclerotic diseases [5]. Cytotoxic T lymphocytes (CTLs)
xert critical protection against viral infection and tumor
ells, however they can also induce harmful reactions such
s autoimmune disease, graft rejection, and graft versus
ost disease (GVHD). Granzyme B/perforin system is mainly
xerted by circulating white blood cells such as CTLs (adap-
ive immune system) and natural killer (NK) cells (innate
mmune system). Granzyme B and perforin are stored in
ecretory granules inside the leukocytes. These molecules
re released outside of the cells by cell to cell contact, inte-
rin engagement with extracellular matrix proteins [6,7],
eceptor activation by cytokines (interleukin-2 and TNF)
8], chemokines (macrophage inﬂammatory protein-1 and
onocyte chemoatatic protein-1) [9,10], and stimulation
y bacteria or lipopolysaccharide. Perforin polymerizes to
orm transmembrane channels and allows granzyme B access
nto target cells (Fig. 1). Granzyme B is a member of the
erine protease family and induces cell death by mecha-
isms such as the activation of caspases, degradation of
tructural proteins and directing the proapoptotic molecule
lymphocyte
Cytotoxic T
Caspases Apoptosis
Caspase 3Mitchondrial cytochrome c
Bid Caspase 8
Target cell
Perforin
Granzyme B
igure 1 Scheme of granzyme B/perforin system. Perforin
olymerizes to form transmembrane channels and allows
ranzyme B access into target cells. Granzyme B, a member
f the serine protease family induces cell death by mechanisms
uch as the activation of caspases, degradation of structural
roteins and directing the proapoptotic molecule Bid to the
itochondrial compartment.
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id to the mitochondrial compartment. To date, ﬁve mem-
ers of granzyme have been identiﬁed: granzyme A, B, H,
, and M. These granzymes are produced as inactive forms
nd are activated by cathepsin C-mediated removal of pro-
eptide [11,12]. Among these enzymes, granzyme A and B
re well characterized. Granzyme A and B are known to be
nvolved in CTL-mediated target cell apoptosis. Granzyme B
leaves Asp or Glu residue of proscaspases, resulting in acti-
ation of caspases cascade. The activated caspases induce
NA fragmentation and cellular apoptosis [13—17]. In normal
onditions, granzymes are playing important roles in elimi-
ation of abnormal cells. Granzyme B-deﬁcient mice show a
ormal phenotype with an exception of reduced activity of
arget cell apoptosis, antiviral activity, and tumor cell elim-
nation [17,18]. Thus granzyme B is playing an important
ole in CTL-mediated immune response. However, previous
tudies have clariﬁed excess production of granzyme B is
nvolved in a number of pathological conditions including
hronic inﬂammatory diseases including rheumatoid arthri-
is, GVHD, as well as cardiovascular diseases [19,20].
Previously the granzyme/perforin system has been
eported to play an important role in acute myocarditis
nd immunological rejection of the transplanted heart. Seko
t al. demonstrated inﬁltration of perforin in the hearts of
ice with acute viral myocarditis, suggesting an important
ole in the mechanism of myocardial damage [21]. They pro-
ided the evidence that CTLs injure cardiac myocytes by
eleasing perforin and may play a critical role in the myocar-
ial damage in acute viral myocarditis. Felzen et al. showed
hat the combination of granzyme A and perforin damages
uinea pig ventricular myocytes [22]. As shown by these
eports, the granzyme/perforin system is predominantly
ocused on cardiovascular diseases with immunological dis-
rders. However, recent studies have demonstrated a role
f the granzyme/perforin system in other cardiovascular
iseases such as chronic angina pectoris, acute coronary
yndrome, and acute myocardial infarction.
therosclerotic disease and granzyme B
ctivation of the immune response is essential to elimi-
ate infected cells and tumor cells in humans. However,
xcess immune response contributes to various pathological
rocesses, i.e. autoimmune disease, chronic obstruc-
ive pulmonary disease, graft versus host reaction, and
therosclerosis. Endothelium has a critical role to prevent
therosclerosis by releasing nitric oxide, producing anti-
oagulant factors, and regulating permeability of circulating
ubstances into vessel walls. Endothelial apoptosis leads to
therosclerotic plaque formation by increasing smooth mus-
le cell proliferation, leukocyte migration into subendothe-
ial layers, thrombus formation, and accumulation of circu-
ating lipids to vessel walls. Clément et al. have reported
hat granzyme B can be a predictive marker for acute GVHD
r cardiac rejection after bone marrow or heart trans-
lantation [23]. Acceleration of coronary atherosclerosis is
ell-known in patients receiving heart transplantation. Choy
t al. have shown the critical role of granzyme B in vascular
isease in patients receiving heart transplantation [24].
Accumulation of T lymphocytes is reported in atheroscle-
otic lesions, in particular, shoulder lesion of the plaques
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Figure 2 The relationship between levels of granzyme B in
the supernatant of cultured peripheral blood mononuclear cells
and TIMI risk score in patients with unstable angina pectoris.
Patients with unstable angina were classiﬁed into ﬁve groups
according to the Thrombolysis In Myocardial Infarction (TIMI)
risk score (TIMI 1, 2, 3, 4, and more than 5). The levels of
granzyme B in the supernatant of cultured peripheral blood
mononuclear cells were elevated when the TIMI risk score
increased (TIMI 1, 14.8± 3.1 pg/mL; TIMI 2, 15.2± 3.4 pg/mL;
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Figure 3 Levels of plasma granzyme B in patients with coro-
nary artery and chronic kidney disease. The Kruskal—Wallis test
revealed that plasma levels of granzyme B in CAD complicated
CKD patients were signiﬁcantly higher than those in patients
with CAD or patients with CKD (CAD, 10.6± 2.8; CKD, 27.3± 3.3;
CAD/CKD, 35.5± 8.1 pg/mL, p < 0.05). *p < 0.05; **p < 0.001.
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ATIMI 3, 25.2± 5.1 pg/mL; TIMI 4, 71.7± 22.3 pg/mL; TIMI 5 and
6, 132± 31.0 pg/mL). *p < 0.05 versus TIMI1 and 3; **p < 0.01
versus TIMI 2; †p < 0.05 versus TIMI 2.
[25—27]. Activated T lymphocytes are supposed to play
an important role in vulnerability of plaques. It has been
reported that expression of matrix degrading enzymes was
increased both in systemic circulation and in vulnera-
ble atheromatous plaques in patients with acute coronary
syndrome. We have observed the increased production
of granzyme B from peripheral blood mononuclear cells
(PBMCs) in patients with unstable angina pectoris [28]
(Fig. 2). We have also found granzyme B expression in
mononuclear cells in ruptured coronary plaques. Impor-
tantly, the granzyme B production from PBMCs was related
to Thrombolysis in Myocardial Infarction (TIMI) risk score
of acute coronary syndrome. Interestingly, studies have
clariﬁed that granzyme B can cleave extracellular matrix
proteins including ﬁbronectin [29], vitronectin, and laminin
[30]. The primary cleavage site of vitronectin was demon-
strated as the Arg-Gly-Asp (RGD) integrin site, which
is consistent with Asp-ase activity of granzyme B. Thus
granzyme B not only induces apoptotic cell death but also
degrades extracellular matrix, leading to weakening of the
ﬁbrous cap of atheromatous plaques. Previous studies have
reported that a number of proteases such as matrix metallo-
proteinases (MMPs), elastases, myeloperoxidase, neutrophil
proteinase 3, and neutral serine proteases (chymase and
tryptase) are supposed to play important roles in degra-
dation of the extracellular matrix, leading to the thinning
and weakening of the ﬁbrous cap [27,31,32]. Among these
enzymes, MMPs have been extensively investigated. Our
results suggest that extracellular granzyme B released from
PBMCs might be another candidate that induces atheroscle-
L
i
tAD, coronary artery disease; CKD, chronic kidney disease;
AD/CKD, patients with both coronary artery and chronic kidney
isease.
otic plaque vulnerability. Recently, Chamberlain et al. have
eported a role of granzyme B in vascular remodeling using
poE and granzyme B double-deﬁcient mice [33]. This study
as shown the evidence that granzyme B directly degrades
xtracellular matrix such as ﬁbrillin-1, leading to an aortic
neurysmal formation.
Normally plasma levels of granzyme B in healthy subjects
s up to 15 pg/mL, which is almost below the detection
imit of enzyme-linked immunosorbent assays. Expression of
ranzyme B is increased in patients with acute inﬂammatory
iseases, malignancy, and GVHD. As shown in Fig. 3, we
ave found that patients with angina pectoris complicated
ith chronic kidney disease (CKD) showed increases in
lasma granzyme B levels compared with CKD alone or
ngina pectoris alone [34]. In particular, plasma granzyme
level was markedly increased in coronary artery disease
atients with end-stage renal disease (ESRD). These results
ight indicate that elevation of plasma granzyme B is one
f the factors that promotes coronary atherosclerosis in
atients with ESRD. A number of epidemiological studies
ave reported that CKD is an independent risk factor
or cardiovascular diseases [35—37]. Although a number
f reports have demonstrated increased cardiovascular
ortality in CKD, the precise mechanisms of how CKD takes
art in the onset of cardiovascular diseases are still not
ully understood. Various cytokines might be involved in
laque formation in patients with CKD. Our data suggest
hat granzyme B can be one of the atherogenic factors in
ubjects such as patients with CKD.
cute myocardial infarction and granzyme Beft ventricular (LV) remodeling after acute myocardial
nfarction (AMI) is a critical complication that leads to
hrombosis, heart failure, and ventricular arrhythmia, lead-
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Figure 4 Correlation between plasma levels of granzyme B
and left ventricular remodeling after acute myocardial infarc-
tion (AMI). The ﬁgure shows simple correlation between plasma
levels of granzyme B on day 14 and the fold-increase in left
ventricular end-diastolic volume index (LVEDVI) over six months
after onset of AMI. There was a signiﬁcant positive correla-
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pion between plasma levels of granzyme B on day 14 and the
old-increase in LVEDVI six months after onset of AMI (r = +0.45,
< 0.01).
ng to an unfavorable clinical outcome [38]. The size of
nfarction determined within several hours after the attack
s the most critical determinant of subsequent heart failure.
owever, mechanical factors, medical interventions, and
umoral factors such as vasoactive substances, growth fac-
ors, and cytokines have been reported to be associated with
V remodeling in the chronic phase after AMI [39—42]. In par-
icular, apoptotic cell death in infarcted tissue is reported
o play an important role in the progression of LV remodeling
fter AMI [43,44]. Hayakawa et al. reported that inhibition
f granulation tissue cell apoptosis by a pancaspase inhibitor
igniﬁcantly improved LV remodeling and heart failure in the
hronic stage after myocardial infarction [45].
We hypothesized that granzyme B is involved in LV
emodeling through induction of apoptotic cell death and
xtracellular matrix degradation activity. We have measured
lasma levels of granzyme B in patients with AMI and found
ncreased plasma levels of granzyme B after AMI [46]. The
lasma levels of granzyme B peaked on day 7 after AMI with a
.6-fold increase compared to that on the day of the admis-
ion. Interestingly, plasma granzyme B level on day 14 after
MI was correlated with increase of LV end-diastolic volume
months after the onset (Fig. 4). TNF and Fas ligand also
ncreased after AMI, however we did not observe a signiﬁ-
ant relationship between these markers and LV remodeling.
n the rat model of AMI, we found that protein expression of
ranzyme B was increased at the infarcted myocardium from
ay 3 to 17 after AMI (unpublished observation). The ﬁnding
s quite interesting to prove increased local expression of
ranzyme B in infarcted myocardium.nhibition of granzyme B
ormally, activity of proteases is tightly regulated to avoid
nfavorable damage of tissues in vivo. For example, MMPs
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re inhibited by binding of their internal inhibitors: tissue
nhibitors of MMPs (TIMPs) in a 1 to 1 molar stoichiometric
ashion. It has been reported that granzyme B is efﬁciently
nhibited by 1-antitrypsin and to a lesser extent by 2-
acrogloblin [47]. However, other reports showed that the
nhibitory action of 1-antitrypsin for granzyme B is still
ontroversial [48,49].
Serpins are a group of proteins with similar struc-
ures that inhibit proteases by forming complexes with
heir proteases. The ﬁrst members of the serpin superfam-
ly extensively studied were antithrombin and antitrypsin,
hich play key roles in controlling blood coagulation and
nﬂammation [50]. Nowadays, more than 1000 serpins have
ow been identiﬁed. Human protease inhibitor-9 (PI-9, ser-
inB9) is a member of the serpin family that has been found
o be an intrinsic inhibitor for granzyme B. PI-9 was originally
ound in T cells to protect themselves against apoptosis by
ecreted granzyme B. It has been reported that PI-9 forms a
omplex with granzyme B and inhibits its activity [51,52].
I-9 is predominately distributed in cytosol and nucleus
ecause it lacks a peptide sequence for secretion. The pres-
nce of circulating PI-9 was proved by Rowshani et al. [53],
owever it is still not clear that circulating PI-9 can inhibit
xtracellular granzyme B in vivo. Kurschus et al. have shown
ctivity of granzyme B is not inhibited by co-incubation with
uman plasma in vitro [49]. However, a protective role of
I-9 and SPI-6, a murine orthologue of human PI-9 against
ranzyme B-induced apoptosis has been reported in both
n vitro and in vivo models [54—56]. Sipione et al. reported
hat Sertoli cells secret another serpin, serpina3n that can
ind and inhibit activity of granzyme B [57]. The regula-
ion mechanism of PI-9 is still not clear. Lazarczyk et al.
ave reported that pentoxifylline upregulated PI-9 mRNA
xpression in human erythroleukemia cell lines [58]. Jiang
t al. have demonstrated that estrogen induces PI-9 expres-
ion in hepatoblastoma cells, HEPG2ER7 cells [59]. Induction
f PI-9 by estrogen might account for a novel mechanism
or estrogen-mediated increase in tumor incidence and gen-
er difference of prevalence in cardiovascular diseases.
nterestingly, Young et al. have demonstrated increased
xpression of interleukin-1 and decreased expression of
I-9 in unstable human atherosclerotic plaques [60]. They
ave demonstrated that PI-9 was an endogenous inhibitor
or interleukin-1 (IL-1)-converting enzyme. Thus admin-
stration of PI-9 inhibits chronic inﬂammation and could be
novel therapeutic tool to treat and prevent cardiovascular
iseases.
Our data suggest that PI-9 can be applicable for pre-
ention of acute coronary syndrome and atherosclerotic
laque formation in patients with CKD and left ventricu-
ar remodeling after AMI. In our preliminary experiments,
arked elevation of granzyme B was found, however no
pparent expression of PI-9 was observed in the infarcted
yocardium of the rat model of AMI. Thus inhibition of
ranzyme B might prevent cardiac rupture and progres-
ion of ventricular remodeling after AMI. Because PI-9 is
redominantly expressed in cytosol, administration of PI-9
an block extracellular granzyme B more efﬁciently. Inter-
stingly, a recent study demonstrated inhibition of IL-1 by
recombinant human IL-1 receptor antagonist (anakinra)
educed left ventricular remodeling [61]. It is possible that
I-9 prevents ventricular remodeling after AMI by inhibit-
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ing IL-1 mediated pathway. To our knowledge, there are few
studies regarding application of granzyme B inhibitor in the
treatment of cardiovascular diseases. Rapamycin treatment
prevents rejection of cardiac allografts via an inhibition
of local granzyme B expression in cardiac allografts in
a mouse model [62]. Suzuki et al. have demonstrated
that plasminogen activator inhibitor-1, of the serpin family
improved the LV function in a porcine model of autoim-
mune myocarditis [63]. These reports support the possibility
of the PL-9 application in various cardiovascular diseases
such as acute coronary syndrome, chronic atherosclerotic
disease, and myocarditis. We also have to be very care-
ful about side effects of granzyme B inhibition such as
disturbance of immune systems and increasing the preva-
lence of malignancy. Several inhibitors for granzyme B
are already available for experiments including Z-AAD-
CMK, Ac-IEPD-CHO, and acethyl-Ile-Glu-Thr-Asp-aldehyde.
So far, these granzyme B inhibitors cannot be applicable
for humans. However, inhibition of granzyme B/perforin sys-
tem by another chemical compound or recombinant protein
could be a new approach to treat human cardiovascular dis-
eases.
Conclusions
Granzyme B could be a novel molecule that plays an impor-
tant role in cardiovascular diseases. It is suggested that
granzyme B is involved in chronic as well as acute inﬂamma-
tion in atherosclerotic coronary artery diseases. Inhibition
of granzyme B could be a novel therapeutic approach to
treating cardiovascular diseases such as prevention of pro-
gression of atherosclerosis, plaque rupture, and ventricular
remodeling after AMI.
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